China Moxifloxacin Market Report 2015-2019
Moxifloxacin was put in the market in Sep. 1999. Having received the approval of American Food and Drug Administration (FDA) on Dec10, 1999, Moxifloxacin entered the US under the trade name of Avelox.
In the second half year of 2002, Moxifloxacin was marketed by The Bayer Group and Beijing Bayer Healthcare Co., Ltd in China. Key markets were major hospitals in large and medium-sized cities in China. Moxifloxacin grew at a rapid pace after entering the Chinese market, with its annual sales value rising from less than CNY 60 million in 2005 to CNY 649 million in 2014 andits CAGR from 2005 to 2014 reaching 30.8%. Moxifloxacin is of great demand in China. Currently, moxifloxacin for sale in China are mainly produced by Nanjing Youke Pharmaceutical CO., Ltd and The Bayer Group whichowns the larger market share of over 95% for sales value in 2014.
As an outstanding antibacterial drug, moxifloxacin is granted with a bright future of application. It is estimated that the moxifloxacin market in China will keep growing in the following few years.
Key Topics Covered:
1 Related Concepts of Moxifloxacin
2 Market Profile of Moxifloxacin in China
3 Survey on Sales Status of Moxifloxacin in China, 2010-2014
4 Survey on Market Share of Major Manufacturers of Moxifloxacin in China, 2010-2014
5 Survey on Dosage Forms of Moxifloxacin in China, 2010-2014
6 Reference Price of Moxifloxacin in Chinese Hospitals in 2014
7 Major Manufacturers of Moxifloxacin in Chinese Market, 2010-2014
8 Market Outlook of Moxifloxacin in China, 2015-2019
Companies Mentioned
- Nanjing Youke Pharmaceutical Co., Ltd- The Bayer Group
For more information visit http://www.researchandmarkets.com/research/9twgkj/investigation
Media Contact:
Laura Wood , +353-1-481-1716, [email protected]
